查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493315

美国多组体学市场规模、份额和趋势分析报告：按产品/服务、按类型、按平台、按应用、按最终用途、细分市场预测，2024-2030 年

U.S. Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By Platform, By Application, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国多组体学市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，美国多组体学市场规模将达到29亿美元，2024年至2030年复合年增长率为15.55%。

市场开拓背后有多种因素，包括体学技术的进步、个人化药物需求的增加、慢性病的传播以及药物发现和开发应用的增加。因此，预计在预测期内美国对多组体学的需求将会增加。

COVID-19 的爆发刺激了美国多组体学产业的进步，加速了研究，推动了诊断创新，并加强了精准医疗。它加速了药物发现，促进了与生物库的合作，并促进了多组体学与远端医疗的整合。透过全面的体学分析，研究人员深入了解了 COVID-19 的发病机制，支持个人化医疗解决方案的开发并加强感染疾病控制工作。

此外，在人工智慧的进一步推动下，多组体学将透过整合基因组学、蛋白质组学和代谢体学的资料来实现生物医学研究的现代化。人工智慧演算法分析复杂的组体学资料集，以揭示分子见解、识别生物标记并预测疾病结果。此次合作将加深我们对生物系统的理解，加速药物发现并促进个人化医疗保健方法，从而推动生物医学的转型。例如，2023 年 5 月，Google云端宣布推出两款新的生命科学领域人工智慧主导解决方案，以加速生物技术、製药和上市公司的药物发现和精准医疗。标靶和先导物识别套件可帮助研究人员识别胺基酸功能并预测蛋白质结构，而多组学套件可快速分析和解释基因组资料并帮助公司创建量身定制的治疗方法。

然而，多组体学技术通常需要在设备、软体和技术人员方面进行大量投资。资料分析和解释的高昂初始成本和持续成本可能会限制采用并阻碍市场成长，特别是在小型研究机构和医疗机构。

美国多组体学市场报告亮点

  • 按产品/服务划分，该产品类别在 2023 年占据市场最大的销售份额。这是由于对能够整合和分析不同组体学资料集的先进技术和工具的需求不断增长。另一方面，预计服务业在预测期内将以最快的复合年增长率成长。
  • 按类型划分，批量多组体学市场在 2023 年占据最大市场占有率。批量多组体学的各种优势归因于其在该领域的主导地位。通常，批量体学对于系统地解释个体层面的疾病发病机制和不同表型至关重要。
  • 基于平台，基因组学领域在市场上占据主导地位，2023 年收益占有率为 39.8%。这是由于不断增长的技术进步和对基因组研究活动的积极投资。同时，由于对个人化药物的需求不断增加，预计从 2024 年到 2030 年，代谢体学领域将以最快的复合年增长率成长。
  • 从应用来看，肿瘤学领域预计将在 2023 年以 40.7% 的收益占有率主导市场，并在预测期内以最快的复合年增长率成长。癌症发生率的上升和多组体学在癌症中的广泛应用预计将推动该领域的成长。
  • 按最终用途划分，学术和研究机构在该领域占据主导地位，到 2023 年销售份额将达到 49.0%。这是由于越来越多的研究和调查集中在基因组学、蛋白质组学、代谢体学和转录组学等多组体学方法。同时，预计 2024 年至 2030 年製药和生技公司将以最快的复合年增长率成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章 产品和服务的业务分析

  • 产品和服务细分仪表板
  • 美国多组体学市场产品与服务波动分析
  • 2018-2030 年美国多组体学市场规模和趋势分析（按产品和服务）
  • 产品
    • 2018-2030 年产品市场估计与预测
    • 装置
    • 消耗品
    • 软体
  • 服务
    • 2018-2030 年服务市场估计与预测

第五章 类型业务分析

  • 类型细分仪表板
  • 美国多组体学市场类型波动分析
  • 2018-2030 年美国多组体学市场规模与趋势分析（按类型）
  • 单细胞多组体学
  • 批量多组体学

第六章 平台业务分析

  • 平台细分仪表板
  • 美国多组体学市场平台波动分析
  • 2018-2030 年美国多组体学市场规模与趋势分析（按平台）
  • 基因组学
  • 转录组学
  • 蛋白质体学
  • 代谢体学
  • 综合体学平台

第七章 应用业务分析

  • 使用细分仪表板
  • 美国多组体学市场应用波动分析
  • 2018-2030 年美国多组体学市场规模与趋势分析（按应用）
  • 细胞生物学
  • 肿瘤学
  • 神经病学
  • 免疫学

第 8 章最终用途业务分析

  • 最终用途细分仪表板
  • 美国多组体学市场的最终用途变化分析
  • 2018-2030 年美国多组体学市场规模与趋势分析（依最终用途）
  • 学术研究所
  • 製药和生物技术公司
  • 其他的

第9章 竞争格局

  • 公司分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/名单
    • BD
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc
    • Danaher
    • PerkinElmer Inc.
    • Shimadzu Corporation
    • Bruker
    • QIAGEN
    • Agilent Technologies, Inc.
    • BGI
Product Code: GVR-4-68040-282-8

U.S. Multiomics Market Growth & Trends:

The U.S. multiomics market size is anticipated to reach USD 2.90 billion by 2030 and is projected to grow at a CAGR of 15.55% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth can be attributed to various factors such as advancements in omics technology, increasing demand for personalized medicines, growing prevalence of chronic diseases, and rising application in drug discovery & development. This has led to an anticipation of increased demand for multiomics in the U.S. over the forecast period.

The COVID-19 pandemic has stimulated advancements in the U.S. multiomics industry, accelerating research, driving diagnostic innovations, and enhancing precision medicine. It has expedited drug discovery, promoted biobanking collaborations, and facilitated the integration of multiomics into telemedicine. Through comprehensive omics analysis, researchers gained insights into COVID-19 pathogenesis, aiding in the development of personalized healthcare solutions and bolstering infectious disease management efforts.

Moreover, multiomics, which is further fueled by AI, modernizes biomedical research by integrating data from genomics, proteomics, and metabolomics. Artificial intelligence algorithms analyze complex omics datasets to uncover molecular insights, identify biomarkers, and predict disease outcomes. This collaboration enhances the understanding of biological systems, accelerates drug discovery, and facilitates personalized healthcare approaches, marking a transformative shift in biomedical sciences. For instance, in May 2023, Google Cloud introduced two novel AI-driven solutions in life sciences for expediting drug discovery and precision medicine for biotech firms, pharmaceutical companies, and public sector entities. The Target and Lead Identification Suite supports researchers in identifying amino acid functionalities and forecasting protein structures, while the Multiomics Suite fast-tracks genomic data analysis and interpretation, empowering companies to devise tailored treatments effectively.

However, multiomics technologies often require substantial investment in equipment, software, and skilled personnel. High initial costs and ongoing expenses for data analysis and interpretation may limit adoption, particularly among smaller research institutions and healthcare facilities, thus hampering the growth of the market.

U.S. Multiomics Market Report Highlights:

  • In terms of products & services, the product segment dominated the market in 2023 with the largest revenue share. This is due to the increasing demand for advanced technologies and tools for enabling the integration & analysis of diverse omics data sets. On the other hand, the services segment is anticipated to grow at the fastest CAGR over the forecast period.
  • Based on type, the bulk multiomics segment held the largest market share in 2023. The various advantages of bulk multiomics can be attributed to the segment's dominance. Typically, bulk multiomics is essential for systematically explaining disorder pathogenesis and different phenotypes at the individual level.
  • Based on platform, the genomics segment dominated the market in 2023 with a revenue share of 39.8%. This is attributed to the growing technological advancements and active investments in genomic research activities. On the other hand, the metabolomics segment is anticipated to grow at the fastest CAGR from 2024 to 2030, owing to the rising demand for personalized medicines.
  • In terms of application, the oncology segment dominated the market in 2023 with a revenue share of 40.7%, and it is expected to grow at the fastest CAGR over the forecast period. The rising incidence of cancer and the growing use of multiomics for cancer are anticipated to drive segment growth.
  • Based on end-use, academic & research institutes dominated the segment with a revenue share of 49.0% in 2023. This is attributed to the increasing studies and research focusing on multiomics approaches, including genomics, proteomics, metabolomics, and transcriptomics. On the other hand, pharmaceutical & biotechnology companies is anticipated to grow at the fastest CAGR from 2024 to 2030.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product & Services Segment
    • 1.1.2. Type Segment
    • 1.1.3. Platform Segment
    • 1.1.4. Application Segment
    • 1.1.5. End-use Segment
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Primary Research
  • 1.5. Information or Data Analysis:
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. The increasing interest of researchers in the field of single-cell genomics
      • 3.2.1.2. Rising incidence of chronic diseases
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High initial costs
      • 3.2.2.2. Stringent government policies and regulations
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

  • 4.1. Product & Services Segment Dashboard
  • 4.2. U.S. Multiomics Market Product & Services Movement Analysis
  • 4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Million)
  • 4.4. Product
    • 4.4.1. Product market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Software
      • 4.4.4.1. Software market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. U.S. Multiomics Market Type Movement Analysis
  • 5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Single-cell Multiomics
    • 5.4.1. Single-cell multiomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Bulk Multiomics
    • 5.5.1. Bulk multiomics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Platform Business Analysis

  • 6.1. Platform Segment Dashboard
  • 6.2. U.S. Multiomics Market Platform Movement Analysis
  • 6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2018 to 2030 (USD Million)
  • 6.4. Genomics
    • 6.4.1. Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Transcriptomics
    • 6.5.1. Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Proteomics
    • 6.6.1. Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Metabolomics
    • 6.7.1. Metabolomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. Integrated Omics Platform
    • 6.8.1. Integrated omics platform market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Application Segment Dashboard
  • 7.2. U.S. Multiomics Market Application Movement Analysis
  • 7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 7.4. Cell Biology
    • 7.4.1. Cell biology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Neurology
    • 7.6.1. Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Immunology
    • 7.7.1. Immunology market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

  • 8.1. End-Use Segment Dashboard
  • 8.2. U.S. Multiomics Market End-Use Movement Analysis
  • 8.3. U.S. Multiomics Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
  • 8.4. Academic & Research Institutes
    • 8.4.1. Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. Pharmaceutical & Biotechnology Companies
    • 8.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. BD
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Illumina, Inc
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Danaher
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. PerkinElmer Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Shimadzu Corporation
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Bruker
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. QIAGEN
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Agilent Technologies, Inc.
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. BGI
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. multiomics market, by product & services, 2018 - 2030 (USD Million)
  • Table 4 U.S. multiomics market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. multiomics market, by platform, 2018 - 2030 (USD Million)
  • Table 6 U.S. multiomics market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. multiomics market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new products/services
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. multiomics market: market outlook
  • Fig. 7 U.S. multiomics competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 U.S. multiomics market driver impact
  • Fig. 10 U.S. multiomics market restraint impact
  • Fig. 11 U.S. multiomics market: Product & services movement analysis
  • Fig. 12 U.S. multiomics market: Product & services outlook and key takeaways
  • Fig. 13 Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Consumables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. multiomics market: Type movement analysis
  • Fig. 19 U.S. multiomics market: Type outlook and key takeaways
  • Fig. 20 Single-cell multiomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Bulk multiomics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. multiomics market: Platform movement analysis
  • Fig. 23 U.S. multiomics market: Platform outlook and key takeaways
  • Fig. 24 Genomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Proteomics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Metabolomics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Integrated omics platform market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. multiomics market: Application movement analysis
  • Fig. 30 U.S. multiomics market: Application outlook and key takeaways
  • Fig. 31 Cell biology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Immunology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. multiomics market: End-use movement analysis
  • Fig. 36 U.S. multiomics market: End-use outlook and key takeaways
  • Fig. 37 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Market share of key market players - U.S. multiomics market